ChemoMetec A/S
CHEMM
ISIN DK0060055861 / Valor 2817833
ChemoMetec A/S
UMushroom community rating:
About company
ChemoMetec A/S is a prominent global manufacturer of cell counting and analysis equipment, known for its high-precision instrumentation that provides reliable data to customers in the biotech, pharmaceutical, and academic sectors. With a focus on developing and producing cutting-edge technology, ChemoMetec serves a wide range of clients worldwide, offering innovative solutions for cell analysis needs.
Summarized from source with an LLMView SourceSector: FinanceLatest Results (16.10.2025):
ChemoMetec A/S reported strong financial results for the third quarter of 2024/25, showcasing significant growth in revenue and operating profit. The company's performance was driven by increased sales across its product lines, successful product launches, and robust activity in key markets.
Revenue Growth
In Q3 2024/25, ChemoMetec A/S achieved a 26% increase in revenue, rising to DKK 124.2 million compared to DKK 98.9 million in the same period last year. For the first nine months of the fiscal year, revenue grew by 26% to DKK 375.7 million.
EBITDA and Margin Improvement
EBITDA surged by 47% to DKK 63.4 million in the third quarter, enhancing the EBITDA margin to 51% from 44% year-over-year. For the nine-month period, EBITDA increased by 46% to DKK 198.6 million, with the margin expanding to 53%.
Instrument Sales Surge
Sales of instruments rose by 23% in Q3 2024/25 to DKK 28.4 million, up from DKK 23.1 million in Q3 2023/24. Over the first nine months, instrument sales grew by 37% to DKK 116.0 million, driven by increased demand for the NC platform and new product introductions.
US Market Performance
Revenue from the USA/Canada region increased by 29% in Q3 2024/25 to DKK 75.7 million, accounting for 60% of total revenue for the nine-month period. The market continues to be a significant contributor to ChemoMetec’s growth.
Product Launch Progress
The launch of the new XcytoMatic products remains on track, with customer validations tripling compared to the previous year. Additionally, the first NC-203 instruments were sold in Q3, marking a milestone in the product development pipeline.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
2018 M
Market cap (USD)
33,179
Daily traded volume (Shares)
508 / 488.8
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
